194 related articles for article (PubMed ID: 37352112)
21. [Cardiovascular events and risk factors in hematological neoplasms patients treated with anthracyclines].
Dai MY; Zhang YL; Sun YX; Lyu X; Zhang XX; Sun XL; Fang FQ; Liu JW; Xia YL; Liu Y
Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Nov; 50(11):1058-1063. PubMed ID: 36418272
[No Abstract] [Full Text] [Related]
22. Risk profiles and incidence of cardiovascular events across different cancer types.
Mitchell JD; Laurie M; Xia Q; Dreyfus B; Jain N; Jain A; Lane D; Lenihan DJ
ESMO Open; 2023 Dec; 8(6):101830. PubMed ID: 37979325
[TBL] [Abstract][Full Text] [Related]
23. Global longitudinal strain at 3 months after therapy can predict late cardiotoxicity in breast cancer.
Liu Z; Liu M; Zhong X; Qin Y; Liang T; Luo T; Yan X; Tang Z; Wang X; Liang S; Li Q; Ruan X; He W; Huang H
Cancer Med; 2023 Jun; 12(12):13374-13387. PubMed ID: 37183826
[TBL] [Abstract][Full Text] [Related]
24. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
[TBL] [Abstract][Full Text] [Related]
25. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
[No Abstract] [Full Text] [Related]
26. Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent.
Søndergaard MMA; Nordsmark M; Nielsen KM; Poulsen SH
JACC CardioOncol; 2021 Dec; 3(5):711-721. PubMed ID: 34988480
[TBL] [Abstract][Full Text] [Related]
27. Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors.
He X; Ji J; Dai X; Qdaisat AZ; Esteva FJ; Hortobagyi GN; Yeung SJ
Clin Cancer Res; 2021 Oct; 27(19):5343-5352. PubMed ID: 34117035
[TBL] [Abstract][Full Text] [Related]
28. Cardiac risk stratification of breast cancer patients in a cardio-oncology clinic.
Doukas PG; Patel RN; Venkatesh V; Khan SS; Baldridge A; Akhter N
Breast Cancer Res Treat; 2021 Nov; 190(1):133-142. PubMed ID: 34390418
[TBL] [Abstract][Full Text] [Related]
29. Haematologic malignancies associated with clozapine
Chrétien B; Lelong-Boulouard V; Chantepie S; Sassier M; Bertho M; Brazo P; Humbert X; Alexandre J; Fedrizzi S; Dolladille C
Psychol Med; 2021 Jul; 51(9):1459-1466. PubMed ID: 32036793
[TBL] [Abstract][Full Text] [Related]
30. Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis.
Rosenkaimer S; Sieburg T; Winter L; Mavratzas A; Hofmann WK; Hofheinz RD; Akin I; Duerschmied D; Hohneck A
Anticancer Res; 2022 Jun; 42(6):3075-3084. PubMed ID: 35641278
[TBL] [Abstract][Full Text] [Related]
31. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
[TBL] [Abstract][Full Text] [Related]
32. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
[TBL] [Abstract][Full Text] [Related]
33. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
34. Risk of primary haematologic cancers following incident non-metastatic breast cancer: A Danish population-based cohort study.
Hjorth CF; Farkas DK; Schapira L; Cullen MR; Sørensen HT; Cronin-Fenton D
Cancer Epidemiol; 2023 Feb; 82():102311. PubMed ID: 36508968
[TBL] [Abstract][Full Text] [Related]
35. Associations of heart failure to prevalence of haematologic- and solid malignancies in southern Sweden: A cross-sectional study.
Scholten M; Halling A
PLoS One; 2023; 18(10):e0292853. PubMed ID: 37831639
[TBL] [Abstract][Full Text] [Related]
36. Right Ventricular Ejection Fraction for the Prediction of Major Adverse Cardiovascular and Heart Failure-Related Events: A Cardiac MRI Based Study of 7131 Patients With Known or Suspected Cardiovascular Disease.
Purmah Y; Lei LY; Dykstra S; Mikami Y; Cornhill A; Satriano A; Flewitt J; Rivest S; Sandonato R; Seib M; Lydell CP; Howarth AG; Heydari B; Merchant N; Bristow M; Fine N; Gaztanaga J; White JA
Circ Cardiovasc Imaging; 2021 Mar; 14(3):e011337. PubMed ID: 33722059
[TBL] [Abstract][Full Text] [Related]
37. Beta-blockers in patients without heart failure after myocardial infarction.
Safi S; Sethi NJ; Korang SK; Nielsen EE; Feinberg J; Gluud C; Jakobsen JC
Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012565. PubMed ID: 34739733
[TBL] [Abstract][Full Text] [Related]
38. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
39. Prospective surveillance and management of cardiac toxicity and health in breast cancer survivors.
Schmitz KH; Prosnitz RG; Schwartz AL; Carver JR
Cancer; 2012 Apr; 118(8 Suppl):2270-6. PubMed ID: 22488701
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
